An observational study in Mucositis and Multiple Myeloma and Plasma Cell Neoplasm, sponsored by Vanderbilt-Ingram Cancer Center. Terminated at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-03-14.
Sponsored by Vanderbilt-Ingram Cancer Center · Observational
RATIONALE: Studying blood or mouthwash samples in the laboratory from patients receiving melphalan for cancer may help doctors learn more about changes that occur in DNA, identify biomarkers related to cancer, and help predict how patients will respond to treatment.
PURPOSE: This clinical trial is studying common genetic mutations related to mucositis in patients with multiple myeloma receiving high-dose melphalan.
OBJECTIVES:
OUTLINE: This is a multicenter study.
Blood or mouthwash samples are collected and DNA isolated from these specimens is analyzed for single nucleotide polymorphisms (SNPs) in LAT1 or other candidate genes. Public databases (i.e., dbSNP and HapMap) are reviewed to select representative SNPs for genotype analysis.
3,632 studies on the registry are indexed under Multiple Myeloma; 745 are open to participants now.
This study's enrollment of 95 is below the median of 140 across 468 observational studies indexed under Multiple Myeloma.
Browse Multiple Myeloma studies →Vanderbilt-Ingram Cancer Center is the lead sponsor of 220 studies on the registry; 32 are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
Counted across the registry records on this site, refreshed daily.
People who have been diagnosed with multiple myeloma and have received or will be receiving high-dose melphalan.
DISEASE CHARACTERISTICS:
Receiving treatment with high-dose melphalan for an autologous stem cell transplantation at any of these facilities:
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
People who have been diagnosed with multiple myeloma and have received high-dose melphalan.
Other: laboratory biomarker analysis
People who have been diagnosed with multiple myeloma and will be receiving high-dose melphalan.
Other: laboratory biomarker analysis
Blood or cheek cells wil be collected.
Association between single nucleotide polymorphisms (SNPs) in genes that encode the melphalan transporters and development and/or severity of mucositis
Time frame: 4 weeks
Association between SNPs in genes that influence melphalan metabolism and development and/or severity of mucositis
Time frame: 4 weeks
This study is terminated, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vanderbilt-Ingram Cancer Center